2025 Clinical practice guidelines for Myocarditises

Russian Society of Cardiology (RSC)

With the participation of: The Eurasian Society of Internists, the Society of Specialists in Heart Failure, the Russian Scientific Medical Society of Internists (RNMOT), the Russian Society of Pathologists, the Russian Society of Radiologists and Radiologists (RORR), the National Association of Experts in Sanatorium Treatment

Approved by the Research and Practical Council of the Ministry of Health of the Russian Federation

1. Maisch B, Pankuweit S. Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy. Herz. 2012;37(6):644-56. doi:10.1007/s00059-012-3679-9.

2. Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28(11):1326-33. doi:10.1093/eurheartj/ehm076.

3. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(6):639-48. doi:10.1161/CIRCULATIONAHA. 108.769489.

4. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250-8. doi:10.1161/01.CIR.0000118493.13323.81.

5. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med. 2010;362(13):1248-9. doi:10.1056/NEJMc0911362.

6. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32(21):2616-25. doi:10.1093/eurheartj/ehr165.

7. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112(13):1965-70. doi:10.1161/CIRCULATIONAHA.105.548156.

8. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol. 2003;42(3):466-72. doi:10.1016/s0735-1097(03)00648-x.

9. Magnani JW, Danik HJ, Dec GW Jr, et al. Survival in biopsy-proven myocarditis: a longterm retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J. 2006;151(2):463-70. doi:10.1016/j.ahj.2005.03.037.

10. Curigliano G, Cardinale D, Suter T, et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155-66. doi:10.1093/annonc/mds293.

11. Arutyunov GP, Kolesnikova EA, Begrambekova YuL, et al. Exercise training in chronic heart failure: practical guidance of the Russian Heart Failure Society. Russ Heart Fail J. 2017;18(1):41-66. (In Russ.) doi:10.18087/rhfj.2017.1.2339.

12. Curigliano G, Cardinale D, Suter T, et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(2):171-90.

13. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-79. doi:10.1002/cncr.11407.

14. Zawadowski GM, Klarich KW, Moder KG, et al. A contemporary case series of lupus myocarditis. Lupus. 2012;21(13):1378-84. doi:10.1177/0961203312456752.

15. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res. 2003;60(1):5-10. doi:10.1016/s0008-6363(03)00437-1.

16. Gauntt C, Huber S. Coxsackievirus experimental heart diseases. Front Biosci. 2003;8: e23-35. doi:10.2741/928.

17. Engler RJ, Nelson MR, Collins LC Jr, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One. 2015;10(3):e0118283. doi:10.1371/journal.pone.0118283.

18. Pankuweit S, Ruppert V, Maisch B. Inflammation in dilated cardiomyopathy. Herz. 2004;29(8):788-93. doi:10.1007/s00059-004-2626-9.

19. Pankuweit S, Portig I, Maisch B. Pathophysiology of cardiac inflammation: molecular mechanisms. Herz. 2002;27(7):669-76. doi:10.1007/s00059-002-2421-4.

20. Maisch B, Ristić AD, Hufnagel G, et al. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol. 2002;11(2):112-22. doi:10.1016/s10548807(01)00113-2.

21. D’Ambrosio A, Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85(5):499504. doi:10.1136/heart.85.5.499.

22. Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245-74. doi:10.1016/j.carpath.2011.10.001.

23. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93(5):841-2. doi:10.1161/01.cir.93.5.841.

24. Mason JW, O’Connell JB, Herskowitz A, et al. The Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333(5):26975. doi:10.1056/NEJM199508033330501.

25. Felker GM, Hu W, Hare JM, et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore). 1999;78(4):270-83. doi:10.1097/00005792-199907000-00005.

26. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867-76. doi:10.1001/jama.296.15.1867.

27. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360(15):1526-38. doi:10.1056/NEJMra0800028.

28. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi:10.1016/S01406736(15)60692-4.

29. Maron BJ, Udelson JE, Bonow RO, et al. American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015;132(22):e273-80. doi:10.1161/CIR.0000000000000239.

30. Karjalainen J, Heikkilä J. Incidence of three presentations of acute myocarditis in young men in military service. A 20-year experience. Eur Heart J. 1999;20(15):1120-5. doi:10.1053/euhj.1998.1444.

31. Arutyunov AG, Rylova AK, Arutyunov GP. Register of hospitalized patients with decompensated circulation (Pavlovsky register). Message 1. Contemporary clinical characteristics and phenotypes of patients with decompensated circulation. Russ Heart Fail J. 2014;15(1):23-32. (In Russ.)

32. Wakafuji S, Okada R. Twenty year autopsy statistics of myocarditis incidence in Japan. Jpn Circ J. 1986;50(12):1288-93. doi:10.1253/jcj.50.1288.

33. Passarino G, Burlo P, Ciccone G, et al. Prevalence of myocarditis at autopsy in Turin, Italy. Arch Pathol Lab Med. 1997;121(6):619-22.

34. Hufnagel G, Pankuweit S, Richter A, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz. 2000;25(3):279-85. doi:10.1007/s000590050021.

35. Kytö V, Sipilä J, Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681-4. doi:10.1136/heartjnl-2013-304449.

36. Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7-46. doi:10.1016/j.cpcardiol.2012.07.003.

37. Saji T, Matsuura H, Hasegawa K, et al. Comparison of the clinical presentation, treatment, and outcome of fulminant and acute myocarditis in children. Circ J. 2012;76(5):1222-8. doi:10.1253/circj.cj-11-1032.

38. Caforio AL, Pankuweit S, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48, 2648a-2648d. doi:10.1093/eurheartj/eht210.

39. Schultz JC, Hilliard AA, Cooper LT Jr, et al. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc. 2009;84(11):1001-9. doi:10.1016/S0025-6196(11)60670-8.

40. Klein RM, Jiang H, Niederacher D, et al. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z Kardiol. 2004;93(4):300-9. doi:10.1007/s00392-004-0079-z.

41. Kühl U, Pauschinger M, Noutsias M, et al. High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With "Idiopathic" Left Ventricular Dysfunction. Circulation. 2005;111(7):887-93.

42. Kuethe F, Lindner J, Matschke K, et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis. 2009;49(11):1660-6. doi:10.1086/648074.

43. Stewart GC, Lopez-Molina J, Gottumukkala RV, et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail. 2011;4(1):71-8. doi:10.1161/CIRCHEARTFAILURE.110.958249.

44. Lassner D, Rohde M, Siegismund C, et al. Myocarditis — Personalized Medicine by Expanded Endomyocardial Biopsy Diagnostics. World J. Cardiovasc. Dis. 2014;04(06):325-40. doi:10.4236/wjcd.2014.46042.

45. Pankuweit S, Moll R, Baandrup U, et al. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol. 2003;34(5):497-503. doi:10.1016/s0046-8177(03)00078-9.

46. Dequin P-F, Heming N, Meziani F, et al. CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(13):1298306. doi:10.1001/jama.2020.16761.

47. Ammirati E, Lupi L, Palazzini M, et al. Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis. Circulation. 2022;145(15):1123-39. doi:10.1161/CIRCULATIONAHA.121.056817.

48. Sabatine M, Poh KK, Mega, Jessica S, et al. Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. The New England journal of medicine. 2007;357(21):2167-78. doi:10.1056/NEJMcpc079030.

49. Cooper LT, Baughman KL, Feldman AM, et al. American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50(19):1914-31. doi:10.1016/j.jacc.2007.09.008.

50. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779-92. doi:10.1016/j.jacc.2011.09.074.

51. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379(9817):738-47. doi:10.1016/S0140-6736(11)60648-X.

52. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29(17):2073-82. doi:10.1093/eurheartj/ehn296.

53. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342(10):690-5. doi:10.1056/NEJM200003093421003.

54. William Dec G. Introduction to Clinical Myocarditis. Myocarditis: From Bench to Bedside/ ed. Cooper L. T. Totowa, NJ: Humana Press. 2003:257-81.

55. Baccouche H, Mahrholdt H, Meinhardt G, et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur Heart J. 2009;30(23):2869-79. doi:10.1093/eurheartj/ehp328.

56. Frustaci A, Verardo R, Caldarulo M, et al. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J. 2007;28(6):733-40. doi:10.1093/eurheartj/ehl525.

57. Dec GW Jr, Waldman H, Southern J, et al. Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol. 1992;20(1):85-9. doi:10.1016/0735-1097(92)90141-9.

58. Ferreira VM, Piechnik SK, Dall’Armellina E, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013;6(10):1048-58. doi:10.1016/j.jcmg.2013.03.008.

59. Abdel-Aty H, Boyé P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815-22. doi:10.1016/j.jacc.2004.11.069.

60. van Nierop J, Limburg A, van Ofwegen-Hanekamp CEE. Myocarditis mimicking acute myocardial infarction. Neth Heart J. 2015;23(10):502-4. doi:10.1007/s12471-015-0732-3.

61. Basman C, Agrawal PR, McRee C, et al. Diagnostic Approach to Myocarditis Mimicking Myocardial Infarction at Initial Presentation. Cardiol Res. 2016;7(6):209-13. doi:10.14740/cr485w.

62. Kühl U, Pauschinger M, Bock T, et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation. 2003;108(8):945-50. doi:10.1161/01.CIR.0000085168.02782.2C.

63. Basic D, Gupta S, Kwong RY. Parvovirus B19-Induced Myocarditis Mimicking Acute Myocardial Infarction: Clarification of Diagnosis by Cardiac Magnetic Resonance Imaging. Circulation. 2010;121(7):e40-2. doi:10.1161/CIR.0b013e3181d310ea.

64. Collier RJ. Diphtheria toxin: mode of action and structure. Bacteriol Rev. 1975;39(1):5485. doi:10.1128/br.39.1.54-85.1975.

65. Stockins BA, Lanas FT, Saavedra JG, et al. Prognosis in patients with diphtheric myocarditis and bradyarrhythmias: assessment of results of ventricular pacing. Br Heart J. 1994;72(2):190-1. doi:10.1136/hrt.72.2.190.

66. Bethell DB, Nguyen MD, Ha TL, et al. Prognostic value of electrocardiographic monitoring of patients with severe diphtheria. Clin Infect Dis. 1995;20(5):1259-65. doi:10.1093/clinids/20.5.1259.

67. Escher F, Pietsch H, Aleshcheva G, et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020;7(5):2440-7. doi:10.1002/ehf2.12805.

68. Wenzel P, Kopp S, Göbel S, et al. Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab. Cardiovasc Res. 2020;116(10):1661-3. doi:10.1093/cvr/cvaa160.

69. Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020;41(39):3827-35. doi:10.1093/eurheartj/ehaa664.

70. Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861-2. doi:10.1093/eurheartj/ehaa286.

71. Nakatani S, Ohta-Ogo K, Nishio M, et al. Microthrombosis as a cause of fulminant myocarditis-like presentation with COVID-19 proven by endomyocardial biopsy. Cardiovasc Pathol. 2022;60:107435. doi:10.1016/j.carpath.2022.107435.

72. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819-24. doi:10.1001/jamacardio.2020.1096.

73. Irabien-Ortiz Á, Carreras-Mora J, Sionis A, et al. Miocarditis fulminante por COVID-19 [Fulminant myocarditis due to COVID-19]. Rev Esp Cardiol. 2020;73(6):503-4. Spanish. doi:10.1016/j.recesp.2020.04.001.

74. Roshdy A, Zaher S, Fayed H, et al. COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies. Front Cardiovasc Med. 2021;7:626975. doi:10.3389/fcvm.2020.626975.

75. Craver R, Huber S, Sandomirsky M, et al. Fatal Eosinophilic Myocarditis in a Healthy 17-YearOld Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c). Fetal Pediatr Pathol. 2020;39(3):263-8. doi:10.1080/15513815.2020.1761491.

76. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-e331. doi:10.1016/S2665-9913(20)30127-2.

77. Yeleti R, Guglin M, Saleem K, et al. Fulminant myocarditis: COVID or not COVID? Reinfection or co-infection? Future Cardiol. 2021;17(8):1307-11. doi:10.2217/fca-2020-0237.

78. Kim IC, Kim JY, Kim HA, et al. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020;41(19):1859. doi:10.1093/eurheartj/ehaa288.

79. Paul JF, Charles P, Richaud C, et al. Myocarditis revealing COVID-19 infection in a young patient. Eur Heart J Cardiovasc Imaging. 2020;21(7):776. doi:10.1093/ehjci/jeaa107.

80. Sinagra G, Porcari A, Merlo M, et al. Myocarditis and pericarditis following mRNA COVID-19 vaccination. Expert opinion of the Italian Society of Cardiology. G. Ital. Cardiol. 2021;22:894-9. doi:10.1714/3689.36747.

81. Sinagra G, Porcari A, Merlo M, et al. 2022 Update on myocarditis and pericarditis following COVID-19 vaccination. Expert Opinion of the Italian Society of Cardiology. G. Ital. Cardiol. (2006) 2022;23:408-13.

82. Mistrulli R, Ferrera A, Muthukkattil ML, et al. SARS-CoV-2 Related Myocarditis: What We Know So Far. J Clin Med. 2023;12(14):4700.

83. Blagova OV, Kogan EA, Lutokhina YA, et al. Subacute and chronic post-covid myoendocarditis: clinical presentation, role of coronavirus persistence and autoimmune mechanisms. Kardiologiia. 2021;61(6):11-27. (In Russ.) doi:10.18087/cardio.2021.6.n1659.

84. Blagova O, Lutokhina Y, Kogan E, et al. Chronic biopsy proven post-COVID myoendocarditis with SARS-Cov-2 persistence and high level of antiheart antibodies. Clin Cardiol. 2022;45(9):952-9. doi:10.1002/clc.23886.

85. Ramírez-García A, Lozano Jiménez S, Darnaude Ximénez I, et al. Pericarditis tras la administración de la vacuna de ARNm BNT162b2 contra la COVID-19 [Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine]. Rev Esp Cardiol. 2021;74(12):11213. Spanish. doi:10.1016/j.recesp.2021.06.006.

86. Maiese A, Baronti A, Manetti AC, et al. Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated? Vaccines (Basel). 2022;10(2):308. doi:10.3390/vaccines10020308.

87. Kim SH, Lee SY, Kim GY, et al. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination. J Korean Med Sci. 2022;37(13):e104. doi:10.3346/jkms.2022.37.e104.

88. Khan MZ, Janus S, Franklin S, et al. COVID-19 Vaccination-Induced Cardiomyopathy Requiring Permanent Left Ventricular Assist Device. Cureus. 2022;14(4):e24477. doi:10.7759/cureus.24477.

89. Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open. 2022;12(5):e059223.

90. Hatziantoniou S, Anastassopoulou C, Lazaros G, et al. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States. Expert Rev Vaccines. 2022;21(11):1691-6. doi:10.1080/1476058 4.2022.2100765.

91. Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169-93. doi:10.1038/s41569-020-00435-x.

92. Kiblboeck D, Klingel K, Genger M, et al. Myocarditis following mRNA COVID-19 vaccination: call for endomyocardial biopsy. ESC Heart Fail. 2022;9(3):1996-2002. doi:10.1002/ehf2.13791.

93. Kounis NG, Koniari I, Mplani V, et al. Hypersensitivity Myocarditis and the Pathogenetic Conundrum of COVID-19 Vaccine-Related Myocarditis. Cardiology. 2022;147(4):413-5. doi:10.1159/000524224.

94. Frustaci A, Verardo R, Galea N, et al. Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination. J Clin Med. 2022;11(6):1660. doi:10.3390/jcm11061660.

95. Okayama K. Comparison of 18F-FDG PET and 67Ga scintigraphy in patients with cardiac sarcoidosis. J Nucl Med. 2015;56(3):343-8.

96. Horiuchi K, Kosugi S, Abe H, et al. Fulminant myocarditis after the first dose of mRNA-1273 vaccination in a patient with previous COVID-19: a case report. Eur Heart J Case Rep. 2022;6(7):ytac290. doi:10.1093/ehjcr/ytac290.

97. Ammirati E, Cavalotti C, Milazzo A, et al. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. Int J Cardiol Heart Vasc. 2021;34:100774. doi:10.1016/j.ijcha.2021.100774.

98. Sinitsyn VE, Stukalova OV, Larina OM, et al. New possibilities in diagnosing non-coronary myocardial lesions: the role of magnetic resonance imaging. Kreativnaya Kardiologiya. 2008;(1):66-73. (In Russ.)

99. Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J. 1999;20(2):93-102. doi:10.1053/euhj.1998.1145.

100. Ferreira V, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. JACC. 2018;72(24): 3158-76.

101. Brown CA, OʼConnell JB. Implications of the Myocarditis Treatment Trial for clinical practice. Curr. Opin. Cardiol. 1996;11(3):332-6.

102. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9. doi:10.1161/01.cir.103.16.2055.

103. Lauer B, Schannwell M, Kühl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol. 2000;35(1):11-8. doi:10.1016/s0735-1097(99)00485-4.

104. Heymans S. Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools. 2007;28(11):1279-80. doi:10.1093/eurheartj/ehm111.

105. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494-502. doi:10.1001/jama.2010.1708.

106. Deardorff R, Spinale FG. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med. 2009;3(5):513-23. doi:10.2217/bmm.09.60.

107. Emdin M, Vittorini S, Passino C, et al. Old and new biomarkers of heart failure. Eur J Heart Fail. 2009;11(4):331-5. doi:10.1093/eurjhf/hfp035.

108. Zhang L, Hu D, Li J, et al. Autoantibodies against the myocardial beta1-adrenergic and M2-muscarinic receptors in patients with congestive heart failure. Chin Med J (Engl). 2002;115(8):1127-31.

109. Maisch B, Richter A, Sandmöller A, et al. BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz. 2005;30(6):535-44. doi:10.1007/s00059-005-2730-5.

110. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107(6):857-63. doi:10.1161/01.cir.0000048147.15962.31.

111. Staudt A, Staudt Y, Dörr M, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J. Am. Coll. Cardiol. 2004;44(4):829-36. doi:10.1016/j.jacc.2004.04.055.

112. Störk S, Boivin V, Horf R, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J. 2006;152(4):697-704. doi:10.1016/j.ahj.2006.05.004.

113. Warraich RS, Noutsias M, Kazak I, et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J. 2002;143(6):1076-84. doi:10.1067/mhj.2002.124406. Erratum in: Am Heart J. 2003;145(2):213. Kasac Ilkay [corrected to Kazak Ilkay].

114. Deubner N, Berliner D, Schlipp A, et al. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail. 2010;12(7):753-62. doi:10.1093/eurjhf/hfq072.

115. Mahfoud F, Gärtner B, Kindermann M, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32(7):897-903. doi:10.1093/eurheartj/ehq493.

116. Liu P, Martino T, Opavsky MA, et al. Viral myocarditis: balance between viral infection and immune response. Can J Cardiol. 1996;12(10):935-43.

117. Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A. 1992;89(1):314-8. doi:10.1073/pnas.89.1.314.

118. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart. 1997;78(6):539-43. doi:10.1136/hrt.78.6.539.

119. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581-90. doi:10.1161/CIRCULATIONAHA.105.606509.

120. Grün S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59(18):160415. doi:10.1016/j.jacc.2012.01.007.

121. Ukena C, Mahfoud F, Kindermann I, et al. Prognostic electrocardiographic parameters in patients with suspected myocarditis. Eur J Heart Fail. 2011;13(4):398-405. doi:10.1093/eurjhf/hfq229.

122. Yilmaz A. Imaging in inflammatory heart disease: from the past to current clinical practice. Hell. J. Cardiol. HJC Hell. Kardiologike Epitheorese. 2009;50(6):449-60.

123. Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36(1):227-32. doi:10.1016/s0735-1097(00)00690-2.

124. Meindl C, Paulus M, Poschenrieder F, et al. Patients with acute myocarditis and preserved systolic left ventricular function: comparison of global and regional longitudinal strain imaging by echocardiography with quantification of late gadolinium enhancement by CMR. Clin Res Cardiol. 2021;110(11):1792-800. doi:10.1007/s00392-021-01885-0.

125. Løgstrup BB, Nielsen JM, Kim WY, et al. Myocardial oedema in acute myocarditis detected by echocardiographic 2D myocardial deformation analysis. Eur Heart J Cardiovasc Imaging. 2016;17(9):1018-26. doi:10.1093/ehjci/jev302.

126. Sperlongano S, D’Amato A, Tagliamonte E, et al. Acute myocarditis: prognostic role of speckle tracking echocardiography and comparison with cardiac magnetic resonance features. Heart Vessels. 2022;37(1):121-31. doi:10.1007/s00380-021-01893-0.

127. Novo G, Di Lisi D, La Franca E, et al. Usefulness of longitudinal systolic strain and delayed enhancement cardiac magnetic resonance in depicting risk of supraventricular arrhythmias in patients with acute myocarditis and preserved left ventricular function. Echocardiography. 2022;39(2):294-301. doi:10.1111/echo.15306.

128. Zuo H, Li H, Li R, et al. Myocardial strain features by 2D-STE during the course of fulminant myocarditis: Correlation with characteristics by CMR and clinical implications. Medicine (Baltimore). 2021;100(15):e25050. doi:10.1097/MD.0000000000025050.

129. Yadav DK, Choudhary S, Gupta PK, et al. The Tei index and asymptomatic myocarditis in children with severe dengue. Pediatr Cardiol. 2013;34(6):1307-13. doi:10.1007/s00246-013-0639-y.

130. Mirna M, Schmutzler L, Vogl F, et al. Tei Index Is a Useful Adjunctive Tool in the Diagnostic Workup of Patients with Acute Myocarditis. J Cardiovasc Dev Dis. 2022;9(8):283. doi:10.3390/jcdd9080283.

131. Fields CL, Ossorio MA, Roy TM, et al. Thallium-201 scintigraphy in the diagnosis and management of myocardial sarcoidosis. South Med J. 1990;83(3):339-42. doi:10.1097/00007611-199003000-00022.

132. Le Guludec D, Menad F, Faraggi M, et al. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest. 1994;106(6):1675-82. doi:10.1378/chest.106.6.1675.

133. O’Connell JB, Henkin RE, Robinson JA, et al. Gallium-67 imaging in patients with dilated cardiomyopathy and biopsy-proven myocarditis. Circulation. 1984;70(1):58-62. doi:10.1161/01.cir.70.1.58.

134. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur. J. Nucl. Med. Mol. Imaging. 2011;38(9):1773-83.

135. Narusov OYu, Alaeva EN, Tereshchenko SN. Diagnostic capabilities of cardiac magnetic resonance imaging in patients with inflammatory cardiomyopathy: comparison of its results with endomyocardial biopsy data and clinical picture. Ter Arkh. 2013;85(4):22-8. (In Russ.)

136. Sinitsyn VE, Mershina EA, Korobkova IZ, et al. Magnetic resonance imaging in the diagnosis of myocarditis and cardiomyopathies. Examination procedure: training and methodological manual. Moscow: KDU; 2024. 65 p. (In Russ.) doi:10.31453/kdu.ru.978-5-00247-010-52024-65.

137. Voigt A, Elgeti T, Durmus T, et al. Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults–towards identification of myocardial inflammation. Eur Radiol. 2011;21(5):925-35. doi:10.1007/s00330-010-1985-2.

138. Friedrich MG, Sechtem U, Schulz-Menger J, et al. International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009;53(17):1475-87. doi:10.1016/j.jacc.2009.02.007.

139. Kellman P, Wilson JR, Xue H, et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14(1):63. doi:10.1186/1532-429X-14-63.

140. Safiullina AA, Narusov OYu, Shariya MA, et al. The role of magnetic resonance imaging in the diagnosis of inflammatory myocardial diseases. Kardiologicheskii Vestnik. 2012;7(1):41-6. (In Russ.) Сафиуллина А. А., Нарусов О. Ю., Шария М. А. и др. Роль магнитно-резонансной томографии в диагностике воспалительных заболеваний миокарда. Кардиологический вестник. 2012;7(1):41-6.

141. Luetkens JA, Homsi R, Dabir D, et al. Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis. J Am Heart Assoc. 2016;5(7):e003603. doi:10.1161/JAHA.116.003603.

142. Gutberlet M, Spors B, Thoma T, et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology. 2008;246(2):401-9. doi:10.1148/radiol.2461062179.

143. Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122(9):900-9. doi:10.1161/CIRCULATIONAHA.109.924167.

144. Chow LH, Radio SJ, Sears TD, et al. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol. 1989;14(4):915-20. doi:10.1016/07351097(89)90465-8.

145. Parrillo JE, Aretz HT, Palacios I, et al. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure. Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis. Circulation. 1984;69(1):93-101. doi:10.1161/01.cir.69.1.93.

146. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.

147. Mirabel M, Luyt CE, Leprince P, et al. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med. 2011;39(5):1029-35. doi:10.1097/CCM.0b013e31820ead45.

148. Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 2011;40(3):682-8. doi:10.1016/j.ejcts.2010.12.050.

149. Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction. BMJ. 1976;1(6018):1121-3. doi:10.1136/bmj.1.6018.1121.

150. Mareev YuV, Mareev VYu. Characteristics and treatment of hospitalized patients with CHF. Kardiologiia. 2017;57(4S):19-30. (In Russ.) doi:10.18087/cardio.2433.

151. Eapen ZJ, Reed SD, Li Y, et al. Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. Circ Heart Fail. 2013;6(4):727-32. doi:10.1161/CIRCHEARTFAILURE.112.000265.

152. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303(17):1716-22. doi:10.1001/jama.2010.533.

153. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 2011;364(9):797-805. doi:10.1056/NEJMoa1005419.

154. Ahmad T, Jackson K, Rao VS, et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation. 2018;137(19):2016-28. doi:10.1161/CIRCULATIONAHA.117.030112.

155. Mareev VYu, Vygodin VA, Belenkov Yu N. Diuretic therapy with effective doses of oral torasemide (Diuver®) and furosemide in patients with exacerbation of chronic heart failure (DUEL-CHF study). Russ Heart Fail J. 2011;12(1):3-10. (In Russ.)

156. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J. Cardiovasc. Pharmacol. 1997;29(3):367-72. doi:10.1097/00005344199703000-00010.

157. Martens P, Nijst P, Mullens W. Current Approach to Decongestive Therapy in Acute Heart Failure. Curr. Heart Fail. Rep. 2015;12(6):367-78. doi:10.1007/s11897-015-0273-5.

158. van Vliet AA, Donker AJ, Nauta JJ, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am. J. Cardiol. 1993;71(3):21A-28A. doi:10.1016/0002-9149(93)90241-4.

159. Butler J, Hernandez AF, Anstrom KJ, et al. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail. 2016;4(9):726-35. doi:10.1016/j.jchf.2016.06.003.

160. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N. Engl. J. Med. 2012;367(24):2296-304. doi:10.1056/NEJMoa1210357.

161. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;2013(8):CD005151. doi:10.1002/14651858.CD005151.

162. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet Lond. Engl. 1998;351(9100):389-93. doi:10.1016/S0140-6736(97)08417-1.

163. Belletti A, Castro ML, Silvetti S, et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br. J. Anaesth. 2015;115(5):656-75. doi:10.1093/bja/aev284.

164. Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290-301. doi:10.1007/s00134-010-2073-4.

165. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am. Heart J. 2007;153(1):98-104. doi:10.1016/j.ahj.2006.09.005.

166. De Backer D, Biston P, Devriendt J, et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. N. Engl. J. Med. 2010;362(9):779-89. doi:10.1056/NEJMoa0907118.

167. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J. Card. Fail. 2010;16(12):922-30. doi:10.1016/j.cardfail.2010.07.246.

168. Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn. Circ. J. 1999;63(12):934-40. doi:10.1253/jcj.63.934.

169. Kivikko M, Pollesello P, Tarvasmäki T, et al. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. Int. J. Cardiol. 2016;215:26-31. doi:10.1016/j.ijcard.2016.04.064.

170. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103-11. doi:10.1016/j.jchf.2012.12.004.

171. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur. Heart J. 2009;30(16):1995-2002. doi:10.1093/eurheartj/ehp249.

172. Chen HS, Wang W, Wu SN, et al. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2013;2013(10):CD004471. doi:10.1002/14651858.CD004471.

173. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 2015;36(41):2793-867. doi:10.1093/eurheartj/ehv316.

174. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an Implantable Cardioverter– Defibrillator for Congestive Heart Failure. N. Engl. J. Med. 2005;352(3):225-37. doi:10.1056/NEJMoa043399.

175. Heart Failure Society Of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12(1):10-38. doi:10.1016/j.cardfail.2005.12.001.

176. Tara S, Yamamoto T, Kanaoka K, et al. Japanese Registry of Fulminant Myocarditis Investigators. Effects of Cardioprotective Drugs on 90-Day Mortality or Heart Transplantation in Patients With Fulminant Myocarditis. Circ Rep. 2024;6(8):322-32. doi:10.1253/circrep. CR-24-0059.

177. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1): 4-131. doi:10.1002/ejhf.2333.

178. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur. Heart J. 2009;30(10):1245-53. doi:10.1093/eurheartj/ehp100.

179. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone Interaction With β-Blockers: Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. Circulation. 1999;99(17):2268-75. doi:10.1161/01.cir.99.17.2268.

180. Kovoor P, Eipper V, Byth K, et al. Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur. Heart J. 1999;20(5):364-74. doi:10.1053/euhj.1998.1279.

181. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am. J. Cardiol. 1993;72(4):44A-50A. doi:10.1016/0002-9149(93) 90024-7.

182. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ. Heart Fail. 2013;6(1):15-22. doi:10.1161/CIRCHEARTFAILURE.112.969261.

183. Schumm J, Greulich S, Wagner A, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J. Cardiovasc. Magn. Reson. Off. J. Soc. Cardiovasc. Magn. Reson. 2014;16(1):14. doi:10.1186/1532-429X-16-14.

184. Galyavich AS, Tereshchenko SN, Uskach TM, et al. Chronic heart failure. Clinical guidelines 2024. Russ J Cardiol. 2024;29(11):6162. doi:10.15829/1560-4071-2024-6162. (In Russ.) doi:10.15829/1560-4071-2024-6162. EDN: WKIDLJ.

185. Tereshchenko SN, Zhirov IV, Masenko VP, et al. Diagnosis and treatment of myocarditis. Eurasian Cardiol J. 2019;(3):4-33. (In Russ.) doi:10.38109/2225-1685-2019-3-4-33.

186. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolismThe Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). Eur. Heart J. 2014;35(43):3033-80. doi:10.1093/eurheartj/ehu283.

187. Büller HR, Prins MH, Lensin AW, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi:10.1056/NEJMoa1113572.

188. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. N. Engl. J. Med. 2012;366(20):1859-69. doi:10.1056/NEJMoa1202299.

189. Schultheiss HP, Piper C, Sowade O, et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2016;105(9):763-73. doi:10.1007/s00392-016-0986-9.

190. Kühl U, Lassner D, von Schlippenbach J, et al. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy. J. Am. Coll. Cardiol. 2012;60(14):1295-6. doi:10.1016/j.jacc.2012.06.026.

191. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006;117(4 Suppl):S525-53. doi:10.1016/j.jaci.2006.01.015.

192. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103(2):220-5. doi:10.1161/01.cir.103.2.220.

193. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89(1):252-7. doi:10.1161/01.cir.89.1.252.

194. Maisch B, Alter P. Treatment options in myocarditis and inflammatory cardiomyopathy: Focus on i.v. immunoglobulins. Herz. 2018;43(5):423-30. doi:10.1007/s00059-018-4719-x.

195. Herda LR, Trimpert C, Nauke U, et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am. Heart J. 2010;159(5):809-16. doi:10.1016/j.ahj.2010.01.012.

196. Bulut D, Scheeler M, Wichmann T, et al. Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2010;99(10):633-8. doi:10.1007/s00392-010-0162-6.

197. Felix SB, Staudt A, Dörffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J. Am. Coll. Cardiol. 2000;35(6):1590-8. doi:10.1016/s0735-1097(00)00568-4.

198. Mobini R, Staudt A, Felix SB, et al. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun. 2003;20(4):345-50. doi:10.1016/s0896-8411(03)00042-8.

199. Legrand F, Klion A. Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects. J. Allergy Clin. Immunol. Pract. 2015;3(2):167-74. doi:10.1016/j.jaip.2015.01.013.

200. Maisch B. Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options. Front Cardiovasc Med. 2019;6:48. doi:10.3389/fcvm.2019.00048.

201. Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. J Am Coll Cardiol. 2017;70(19):2363-75. doi:10.1016/j.jacc.2017.09.023.

202. Ammirati E, Stucchi M, Brambatti M, et al. Eosinophilic myocarditis: a paraneoplastic event. Lancet. 2015;385(9986):2546. doi:10.1016/S0140-6736(15)60903-5. PMID: 26122067.

203. Akuthota P, Weller PF. Spectrum of Eosinophilic End-Organ Manifestations. Immunol. Allergy Clin. North Am. 2015;35(3):403-11. doi:10.1016/j.iac.2015.04.002.

204. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J. Allergy Clin. Immunol. 2009;124(6):1319-25.

205. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-100. doi:10.1002/art.1780330806.

206. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215-28. doi:10.1056/NEJMoa070812.

207. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med. 2021;384:1491-502. doi:10.1056/NEJMoa2100433.

208. Gupta S, Wang W, Hayek SS, et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern. Med. 2021;181:41-51.

209. Blagova O, Yuliya L, Savina P, et al. Corticosteroids are effective in the treatment of viruspositive post-COVID myoendocarditis with high autoimmune activity. Clin Cardiol. 2023;46(3):352-4. doi:10.1002/clc.23978.

210. Piepoli MF, Crisafulli A. Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes. Exp. Physiol. 2014;99(4):609-15.

211. Ribeiro JP, Chiappa GR, Callegaro CC. The contribution of inspiratory muscles function to exercise limitation in heart failure: pathophysiological mechanisms. Rev. Bras. Fisioter. Sao Carlos Sao Paulo Braz. 2012;16(4):261-7.

212. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010;12(7):706-15. doi:10.1093/eurjhf/hfq056.

213. Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8(1):33-40. doi:10.1161/CIRCHEARTFAILURE.114.001615.

214. Corrà U, Agostoni PG, Anker SD, et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(1):3-15. doi:10.1002/ejhf.979.

215. Bellet RN, Adams L, Morris NR. The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness — a systematic review. Physiotherapy. 2012;98(4):277-86. doi:10.1016/j.physio.2011.11.003.

216. Arutyunov GP. Issues of non-pharmacological treatment in patients with heart failure. Russ Heart Fail J. 2001;2(1):35-6. (In Russ.)

217. Callegaro CC, Martinez D, Ribeiro PA, et al. Augmented peripheral chemoreflex in patients with heart failure and inspiratory muscle weakness. Respir Physiol Neurobiol. 2010;171(1):31-5. doi:10.1016/j.resp.2010.01.009.

218. Shah P, Pellicori P, Macnamara A, et al. Is Swimming Safe in Heart Failure? A Systematic Review. Cardiol Rev. 2017;25(6):321-5. doi:10.1097/CRD.0000000000000154.

219. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2015;28(1):1-39.e14.

220. Savina PO, Blagova OV, Ainetdinova DKh, et al. Subacute and chronic post-COVID myocarditis: diagnosis, clinical variants, treatment approaches. Russ J Cardiol. 2024;29(11):6089. (In Russ.) doi:10.15829/15604071-2024-6089. EDN: EYNACD.

221. Rector TS, Kubo SH, Cohn JN. Patients’ self-assessment of their congestive heart failure: content, reliability and validity of a new measure — the Minnesota Living with Heart Failure questionnaire. Heart Fail. 1987;3:198-209.

222. Ammirati E, Frigerio M, Adler ED, et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ Heart Fail. 2020;13(11): e007405. doi:10.1161/CIRCHEARTFAILURE.120.007405.

223. Kociol RD, Cooper LT, Fang JC, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. Circulation. 2020;141(6):e69-e92. doi:10.1161/CIR.0000000000000745.

224. Truong K, Kelly S, Bayly A, Smith A. Successful mepolizumab treatment for DRESSinduced refractory eosinophilic myocarditis and concurrent thyroiditis. BMJ Case Rep. 2021;14(7):e242240. doi:10.1136/bcr-2021-242240.

225. Higashitani K, Yoshimi R, Sato Y, et al. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis. Mod Rheumatol Case Rep. 2022;6(1):87-92. doi:10.1093/mrcr/rxab022.

226. Chabior A, Tymińska A, Pawlak A, et al. Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology. Cardiol J. 2024;31(2):342-51. doi:10.5603/cj.95175.

227. Drozdov DV, Makarov LM, Barkan VS, et al. Standard 12-lead resting electrocardiogram recording in adults and children, 2023: methodological guidelines. Russ J Cardiol. 2023;28(10):5631. (In Russ.) acic echocardiography: methodological guidelines 2024. Russ J Cardiol. 2025;30(2):6271. (In Russ.) doi:10.15829/1560-4071-2025-6271.

228. Asada AM, Kahwash R, Trovato V. Eosinophilic myocarditis: a concise review. Curr Cardiol Rep. 2025;27(1):38. doi:10.1007/s11886-024-02184-6.

229.